期刊
CARDIOVASCULAR RESEARCH
卷 119, 期 9, 页码 1787-1798出版社
OXFORD UNIV PRESS
DOI: 10.1093/cvr/cvad095
关键词
Non-alcoholic liver disease; NAFLD; Cardio vascular disease; Treatment; Pathophysiology; Diagnosis
The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing due to global obesity epidemic. It is a systemic metabolic disease accompanied by insulin resistance and inflammation. While simple hepatic steatosis is the most common manifestation, around 10-20% of individuals with NAFLD have a more progressive disease course characterized by liver fibrosis and inflammation. NAFLD can progress to liver cirrhosis and hepatocellular carcinoma. Weight loss and lifestyle changes are the main treatments, and there are several promising medical treatment options currently under investigation.
The prevalence of non-alcoholic fatty liver disease (NAFLD) is continually increasing due to the global obesity epidemic. NAFLD comprises a systemic metabolic disease accompanied frequently by insulin resistance and hepatic and systemic inflammation. Whereas simple hepatic steatosis is the most common disease manifestation, a more progressive disease course characterized by liver fibrosis and inflammation (i.e. non-alcoholic steatohepatitis) is present in 10-20% of affected individuals. NAFLD furthermore progresses in a substantial number of patients towards liver cirrhosis and hepatocellular carcinoma. Whereas this disease now affects almost 25% of the world's population and is mainly observed in obesity and type 2 diabetes, NAFLD also affects lean individuals. Pathophysiology involves lipotoxicity, hepatic immune disturbances accompanied by hepatic insulin resistance, a gut dysbiosis, and commonly hepatic and systemic insulin resistance defining this disorder a prototypic systemic metabolic disorder. Not surprisingly many affected patients have other disease manifestations, and indeed cardiovascular disease, chronic kidney disease, and extrahepatic malignancies are all contributing substantially to patient outcome. Weight loss and lifestyle change reflect the cornerstone of treatment, and several medical treatment options are currently under investigation. The most promising treatment strategies include glucagon-like peptide 1 receptor antagonists, sodium-glucose transporter 2 inhibitors, Fibroblast Growth Factor analogues, Farnesoid X receptor agonists, and peroxisome proliferator-activated receptor agonists. Here, we review epidemiology, pathophysiology, and therapeutic options for NAFLD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据